BRIEF—Pharnext CEO quits

At French AI-driven biopharma company Pharmnext’s board of directors meeting held yesterday, Dr David Horn Solomon presented his resignation, with immediate effect, from his duties as chief executive and director of Pharnext.

Effective November 27, 2022, Joshua Schafer will serve as interim CEO while retaining his role as chairman, ensuring the continuity of the development of the company and PXT3003, which is currently undergoing a pivotal Phase III clinical trial in patients with Charcot-Marie-Tooth disease type 1A, the PREMIER study, and whose results are expected by the end of 2023.

Following the advice of its Compensation and Nomination Committee, the board has chosen Dr Jim Kuo, currently “observer of the company, to immediately succeed Dr Solomon as director.